Verrica Q4 Net Loss Narrows to $8.1M as YCANTH Rx Rollout Expands
Verrica reported a GAAP net loss of $8.1 million in Q4 2025, narrowing year-over-year losses and driving revenue growth as U.S. applicator sales rebounded following field force expansions. The company continues rolling out YCANTH Rx to new prescribers while finalizing bids and timelines for the VP-315 Phase 3 program.
1. Q4 Financial Performance
Verrica posted a GAAP net loss of $8.1 million in the fourth quarter of 2025, an improvement from the prior year. U.S. revenue grew as applicator sales rebounded in February following strategic field force expansions.
2. YCANTH Rx Commercial Expansion
Leadership highlighted ongoing rollout of YCANTH Rx to additional prescribers, supported by enhanced patient hub services aimed at simplifying access. Coverage improvements in Medicaid and commercial channels, combined with targeted efforts toward pediatricians and dermatologists, underpin growth objectives.
3. VP-315 Phase 3 Program
The company is finalizing bids and timelines for the VP-315 Phase 3 trial, following favorable FDA feedback on study design. Full development program scope and cost estimates remain under review, leaving budget and timing details subject to confirmation.